Targeted delivery of therapeutics to the heart with calcium phosphate nanoparticles
CaP NPs represent a highly promising platform for cardiovascular therapy. Their safety and potential for noninvasive inhalation administration could enable precise, effective, and patient-friendly treatments. Future research, including comparative studies with other nanocarriers, will help to validate their therapeutic potential. Continued development of CaP NP-based strategies may transform CVD management by enabling molecular-level interventions that improve clinical outcomes, reduce systemic side effects, and allow rapid and convenient dosing.
Authors
- Lorenzo Degli Esposti (ORCID: https://orcid.org/0000-0002-6596-560X)
- Federica Mancini (ORCID: https://orcid.org/0000-0002-9099-2861)
- Michele Iafisco (ORCID: https://orcid.org/0000-0002-7813-8347)
- Alessio Adamiano (ORCID: https://orcid.org/0000-0002-2077-0411)
- Camilla Fusacchia (ORCID: https://orcid.org/0009-0008-7643-8777)
Institutions
- University of Parma (IT)
- Institute of Science and Technology for Ceramics (IT)
- National Research Council (IT)
- University of Genoa (IT)
Publication Details
- Journal
- Expert Opinion on Drug Delivery
- Published
- 2025-12-03
- DOI
- https://doi.org/10.1080/17425247.2025.2599851
- Primary Topic
- Inhalation and Respiratory Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00